Back

Clinical and demographic predictors of attenuated LDL-C response to PCSK9 inhibition with bococizumab: Insights from the SPIRE trials.

3 September 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 6 - Lipids Drug therapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Hasan Siddiqi

Brigham and Women's Hospital, Boston (United States of America)

13 More presentations in this session

Presentation thumbnail
Doctor H. Iwata (Tokyo, JP)
Abstract
Presentation thumbnail
Professor E. Liberopoulos (Athens, GR)
Abstract Slides
Presentation thumbnail
Doctor M. Mefford (Birmingham, US)
Abstract
Presentation thumbnail
Doctor D. Dhindsa (Atlanta, US)
Abstract
Presentation thumbnail
Professor E. Liberopoulos (Athens, GR)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 6 - Lipids

The Event

Event poster

ESC Congress 2019

3 September 2019 08:30 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Webinar
New trial evidence in the field of lipid management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources